Jefferies London: While in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year
Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.
Coverage brought to you by










.png)
